LynxDx provides MyProstateScore 2.0, a urine test that analyzes 18 gene transcripts to predict the presence of clinically significant prostate cancer. This technology offers physicians a reliable risk assessment tool, enhancing decision-making for patients with prior negative biopsies and reducing unnecessary repeat procedures.
Funding
$930K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The decision to perform a prostate biopsy, particularly after a prior negative result, presents a challenge due to the risks and discomfort associated with the procedure. Current methods for assessing prostate cancer risk may lack the accuracy needed to confidently guide biopsy decisions, potentially leading to unnecessary procedures.
Solution
LynxDx offers MyProstateScore 2.0 (MPS2), a urine-based molecular diagnostic test that predicts the presence of clinically significant prostate cancer. MPS2 analyzes the expression of 18 unique gene transcripts, providing a comprehensive risk assessment. The test can be used for patients undergoing an initial biopsy or those with a prior negative biopsy. MPS2 results are delivered in an individualized report, tailored to the patient's unique clinical context, to aid physicians in making informed decisions about the need for a prostate biopsy. The test can be run as a biomarker-only test or inclusive of clinical risk factors, depending on provider preference. By providing a more accurate risk assessment, MPS2 helps reduce the number of unnecessary repeat biopsies.
Target Audience
The primary users are urologists and other physicians who manage patients at risk for prostate cancer and need assistance in determining the necessity of a prostate biopsy.
Features
- Analyzes 18 unique gene transcripts in a urine sample to predict the presence of clinically significant prostate cancer.
- Provides an individualized report with results tailored to the patient's unique clinical context.
- Can be used for patients undergoing an initial biopsy or those with a prior negative biopsy.
- Offers flexibility to be run as a biomarker-only test or inclusive of clinical risk factors.
- Utilizes an algorithm developed to optimize diagnostic accuracy.
- Facilitates at-home sample collection.